Treatment News : Long-Acting PrEP Injection Prevents Anal Simian HIV Transmission

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 13, 2013

Long-Acting PrEP Injection Prevents Anal Simian HIV Transmission

CROI 2013A long-acting, injectable version of the antiretroviral dolutegravir prevented rectal transmission of simian HIV (SHIV) in eight macaques, the National AIDS Treatment Advocacy Project reports. Presenting their findings at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, investigators working in collaboration with GlaxoSmithKline (GSK) tested the nanoparticle-encased GSK1265744LAP (GSK744), which is a dolutegravir analog that has such a long half-life that monthly or even quarterly dosing is possible.

Eight macaques were given two injections of GSK744 as pre-exposure prophylaxis (PrEP), the first a week before exposure to SHIV and the second four weeks later. Another eight control macaques did not receive the injections. Then all of the primates were exposed rectally to SHIV each week for up to eight weeks.

All the macaques in the control group were infected with SHIV after a median two exposures, with a range of one to seven weeks. None of those who received the PrEP injections showed signs of infection during the eight weeks of exposures or for three weeks following. The investigators plan to continue monitoring all the macaques for at least 10 weeks after the last SHIV exposure.

All of the primates tolerated the drug well. The investigators concluded that GSK744 appears to be a promising avenue for PrEP among humans with either monthly or quarterly dosing. Considering that a major study of PrEP in African women recently failed because of adherence challenges, an agent requiring such infrequent dosing may be more in line with the needs of such a population and thus answer the problems that plagued that research.

To read the NATAP report, click here.

To read the conference abstract, click here

Search: simian HIV, SHIV, PrEP, pre-exposure prophylaxis, dolutegravir, macaque, National AIDS Treatment Advocacy Project, 20th Conference on Retroviruses and Opportunistic Infections, CROI, nanoparticle, anal exposure.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.